Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Alexis Dieter

Urogynecology and Reconstructive Pelvic Surgery Washington, DC Medical Doctor

NPI 1346408994 CMS profile 1309954

106 Irving St Nw Ste 405, Washington, DC 20010

Open in the dashboard

General payments

$3,130

32 records reported · program years 2020–2025

Research payments

$20,277

Paid to them · 2 records reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$161,131 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Alexis Dieter of Washington, DC is reported in the CMS Open Payments database as having received $3,130 across 32 general payments and $20,277 in research payments paid to them. Separately, studies naming them as principal investigator received $161,131 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $515 5
2024 General $945 8
2023 General $201 2
2022 General $1,329 13
2022 Research $20,277 2
2021 General $95 3
2020 General $44 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexis Dieter
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Alexis Dieter were reported at $515. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Alexis Dieter Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $0 $358 $132–$1,270 $163
2020 $44 $198 $86–$642 $114
2021 $95 $361 $118–$1,182 $132
2022 $1,329 $410 $128–$1,175 $149
2023 $201 $434 $152–$1,344 $160
2024 $945 $494 $193–$1,331 $164
2025 $515 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Coloplast Corp $1,796 15 payments
  2. Boston Scientific Corporation $540 5 payments
  3. Axonics Modulation Technologies, Inc. $411 4 payments
  4. CONMED Corporation $169 1 payment
  5. Caldera Medical, Inc $74 2 payments
  6. Intuitive Surgical, Inc. $44 1 payment
  7. Applied Medical Resources Corporation $28 1 payment
  8. AbbVie, Inc. $25 1 payment
  9. Renovia Inc $22 1 payment
  10. Sumitomo Pharma America, Inc. $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $2,628 28 payments
  2. Travel and Lodging $502 4 payments
Products named General payments · program years 2020–2025
  1. Altis $730 6 payments
  2. Axonics $411 4 payments
  3. Upsylon $322 2 payments
  4. Advantage System $217 3 payments
  5. AIRSEAL $169 1 payment
  6. Desara $74 2 payments
  7. Da Vinci Surgical System $44 1 payment
  8. BOTOX $25 1 payment
  9. Leva Pelvic Floor Trainer $22 1 payment
  10. GEMTESA $22 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2020–2025
  1. Coloplast Corp $20,277 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

173

Median for Urology: 1,053

Drug cost

$74,807

Median for Urology: $101,464

Branded share of claims

71.1%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 42 $32,078
Myrbetriq Mirabegron Brand 31 $28,199
Trospium Chloride Er Trospium Chloride Brand 50 $11,400
Estradiol Generic 50 $3,129

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$67,795

Medicare's payments for the services billed

Medicare patients

192

Average age 76

Services billed

1,468

192 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Diabetes 39%
Ischemic heart disease 20%
Chronic kidney disease 20%
Osteoporosis 20%
Cancer 15%
Depression 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

34 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record